易瑞生物(300942) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥76,346,216.83, representing a 40.34% increase year-over-year[5] - Net profit attributable to shareholders was ¥15,683,546.58, a significant increase of 187.43% compared to the same period last year[5] - The basic earnings per share (EPS) was ¥0.0391, reflecting a growth of 187.50% year-over-year[5] - Total operating revenue increased to ¥185,633,642.05, up 17.5% from ¥158,047,893.25 in the previous period[18] - Net profit for the period reached ¥18,807,119.87, significantly higher than ¥2,987,228.32 from the previous period, marking a 529.5% increase[19] - Earnings per share (EPS) improved to ¥0.0449, compared to ¥0.0097 in the previous period, representing a 363.9% increase[20] - The company reported a total comprehensive income of ¥18,698,893.43, compared to ¥2,922,366.69 in the previous period, reflecting a substantial increase[20] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,481,560,034.85, an increase of 1.67% from the previous year[5] - Total current assets at the end of the reporting period amount to 775,373,728.96 CNY, an increase from 751,616,151.89 CNY at the beginning of the period[15] - Total non-current assets are 706,186,305.89 CNY, slightly up from 705,549,784.03 CNY[15] - Total liabilities decreased to ¥571,208,353.56 from ¥586,923,364.94, a reduction of 2.4%[16] - Total equity attributable to shareholders increased to ¥908,090,377.01 from ¥869,005,338.22, a growth of 4.5%[16] Cash Flow - Cash flow from operating activities showed a decline of 51.16% year-to-date, totaling ¥7,828,976.36[5] - Cash inflow from operating activities totaled ¥206,284,991.21, an increase from ¥183,656,359.44, reflecting a growth of 12.2%[21] - The net cash flow from operating activities decreased to $7,828,976.36 from $16,031,477.88, representing a decline of approximately 51.1% year-over-year[22] - The net cash flow from investing activities improved significantly to $154,991,728.36 compared to a negative cash flow of $315,617,017.17 in the previous period[22] - Cash and cash equivalents at the end of the period increased to $398,991,770.35 from $212,754,799.40, marking a net increase of $141,859,810.93[22] - The company reported a cash inflow of $26,928,827.62 from financing activities, down from $52,000,000.00, a decrease of approximately 48.2%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,436[11] - The largest shareholder, Yirui (Hainan) Venture Capital Co., Ltd., holds 32.68% of shares, totaling 132,369,971 shares[11] - The second-largest shareholder, Zhu Hai, owns 14.85% of shares, amounting to 60,171,195 shares[11] Operational Costs and Expenses - Total operating costs rose to ¥181,665,643.90, compared to ¥158,868,141.37, reflecting a 14.4% increase[18] - Research and development expenses were ¥30,819,335.83, up from ¥28,803,950.34, indicating a 7.0% increase[19] Cash Management - The cash received from investment activities increased by 33.87%, totaling ¥686,213,774.35, primarily due to the redemption of financial products[9] - The company experienced a 70.03% decrease in cash paid for the acquisition of fixed assets, totaling ¥32,164,358.98[9] - Total cash outflow from financing activities was $51,094,548.12, up from $20,326,577.48, indicating a significant increase in financing costs[22] - The cash paid for operating activities totaled $198,456,014.85, an increase from $167,624,881.56, indicating a rise of about 18.3%[22] - The cash received from investment recoveries was $20,598,934.48, down from $34,161,616.16, reflecting a decline of about 39.5%[22] - The company’s total cash outflow for investing activities was $586,485,714.74, a decrease from $864,388,277.17, indicating a reduction of approximately 32.2%[22] - The impact of exchange rate changes on cash and cash equivalents was positive at $3,204,826.71, compared to a negative impact of $932,712.50 in the previous period[22]